European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Role of surgical staging and adjuvant treatment in uterine serous carcinoma
M. K. Frey1, S. Bashir1, N. M. Ward1, K. J. Hensel2, T. A. Caputo1, K. M. Holcomb1, R. Baergen3, D. Gupta1,*
1 Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Weill Cornell Medical College, New York Presbyterian Hospital
2 Department of Pediatrics, Division of Infectious Diseases, Columbia University Medical Center, New York
3 Department of Pathology, Weill Cornell Medical College, New York Presbyterian Hospital, New York (USA)
Eur. J. Gynaecol. Oncol. 2013, 34(5), 453–456;
Published: 10 October 2013
Purpose of investigation: This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence. Materials and Methods: Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared. Results: Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043). Conclusion: In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS.
Uterine serous carcinoma